-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Bx9u7KaUU/tCW9TPLc7k5cEF48F1EzVaa3Y7X8s0v/N4LuVK/C9St9gNfkp9676L ZSk/A6UKgrjEZIjlsDkFkg== 0001127602-10-005127.txt : 20100217 0001127602-10-005127.hdr.sgml : 20100217 20100217170456 ACCESSION NUMBER: 0001127602-10-005127 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100212 FILED AS OF DATE: 20100217 DATE AS OF CHANGE: 20100217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDS ARTHUR T CENTRAL INDEX KEY: 0001134106 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 10613533 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-02-12 0001062822 LEXICON PHARMACEUTICALS, INC./DE LXRX 0001134106 SANDS ARTHUR T 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 1 1 President & CEO Common Stock 2010-02-12 4 F 0 14872 1.91 D 757516 D Common Stock 817500 I By Sands Associates L.P. Common Stock 60000 I By Spouse As Custodian For Children Stock Option (Right to Buy) 1.90 2010-02-15 4 A 0 765000 0 A 2020-02-15 Common Stock 765000 765000 D Restricted Stock Units (Phantom Stock) 2010-02-15 4 A 0 73700 0 A Common Stock 73700 73700 D Withholding of a portion of vested shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/15/2011) and vests 1/48th per month for each month of service thereafter. Each restricted stock unit represents a contingent right to receive one share of common stock. Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent. /s/ Arthur T. Sands, M.D., Ph.D. 2010-02-17 -----END PRIVACY-ENHANCED MESSAGE-----